78 completed, 61 recruiting, 36 unknown, 20 terminated. 67 Not applicable, 52 Phase 1, 47 Phase 2, 10 Phase 3, 6 Early Phase 1.
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Symptom Monitoring and Management Intervention After CAR-T WAYPOINT - Chimeric Antigen Receptor T-cell Therapy, Hematologic Malignancy | Not applicable | Not yet recruiting | Massachusetts General Hospital | 65 | 2027-03-01 | 2026-10-23 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 70 | 2026-10-03 | 2026-08-28 |
| CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation CD45RA-depleted DLI - Hematologic Malignancy, Haplo-identical HCT | Phase 1 | Not yet recruiting | Ruijin Hospital | 30 | 2026-07-01 | 2026-06-29 |
| Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. Allogeneic TCR-enhanced Vδ2 T cell Injection, Cyclophosphamide injection, Fludarabine Injection - Hematologic Malignancy, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 24 | 2026-06-05 | 2026-06-08 |
| CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy, Haplo-identical HCT | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 30 | 2026-06-01 | 2026-06-23 |
| Allergy Delabeling in Antibiotic Stewardship - Intervention RENEW-IN Algorithm for assessment of a beta-lactam intervention, EMR Review - Beta Lactam Allergy, Hematologic Malignancy | Phase 4 | Recruiting | Abramson Cancer Center at Penn Medicine | 3800 | 2026-04-20 | 2026-06-17 |
| Assessing DCog Short for Neurotoxicity in CAR-T DCog Short - Neurotoxicity, Neurotoxicity Syndromes | Not applicable | Recruiting | Beth Israel Deaconess Medical Center | 40 | 2026-04-13 | 2026-10-08 |
| Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant Arm 1 - Leukemia, Lymphoma | Recruiting | National Cancer Institute (NCI) | 88 | 2026-03-04 | 2026-11-06 | |
| Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT Maribavir - Hematologic Malignancy | Phase 3 | Recruiting | Ruijin Hospital | 218 | 2026-02-28 | 2026-04-06 |
| Expressive Writing Program Among Young Adults With Blood Cancer Expressive Writing Workshop - Hematologic Malignancy | Not applicable | Active not recruiting | Blood Cancer United | 100 | 2026-02-01 | 2026-08-13 |
| Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123 - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Enrolling by invitation | AvenCell Therapeutics, Inc. | 178 | 2026-01-29 | 2026-03-16 | |
| ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period Standard of Care, Virtual Reality intervention - Hematologic Malignancy | Not applicable | Recruiting | Wake Forest University Health Sciences | 160 | 2026-01-23 | 2026-07-23 |
| Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy B-ALL, Hematologic Malignancy | Recruiting | St. Jude Children's Research Hospital | 100 | 2026-01-20 | 2026-11-04 | |
| Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment Nite2Day+ - Hematologic Malignancy | Not applicable | Recruiting | Duke University | 60 | 2026-01-14 | 2026-07-08 |
| Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation Primary palliative care - Hematopoietic Cell Transplant, Hematologic Malignancy | Not applicable | Recruiting | Massachusetts General Hospital | 40 | 2026-01-05 | 2026-04-24 |
| HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT Abatacept - Hematologic Malignancy | Early Phase 1 | Recruiting | Duke University | 10 | 2025-11-12 | 2026-11-06 |
| Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies Hematologic Malignancy | Recruiting | University Hospital, Basel, Switzerland | 350 | 2025-10-29 | 2025-12-23 | |
| TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Thymoglobulin, Cyclophosphamide, Fludarabine - Hematologic Malignancy | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 30 | 2025-09-25 | 2026-06-02 |
| HEME Home Transfusion Program HEME-Hospice Program - Leukemia, Myeloma | Not applicable | Recruiting | Dana-Farber Cancer Institute | 700 | 2025-09-10 | 2026-10-28 |
Showing 20 of 232. Sign in to see all of them.
Hematologic Neoplasms (232) · Leukemia, Myeloid, Acute (29) · Lymphoma (26) · Leukemia (23) · Neoplasms (22) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (20) · Myelodysplastic Syndromes (18) · Lymphoma, Non-Hodgkin (14) · Multiple Myeloma (14) · Hodgkin Disease (11) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (10) · Graft vs Host Disease (9) · Hematologic Diseases (7) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, B-Cell (7)
Hemic and Lymphatic Diseases (232) · Neoplasms by Site (231) · Hematologic Diseases (225) · Neoplasms (210) · Neoplasms by Histologic Type (61) · Immune System Diseases (59) · Pathological Conditions, Signs and Symptoms (53) · Immunoproliferative Disorders (48) · Lymphatic Diseases (48) · Lymphoproliferative Disorders (47) · Pathologic Processes (44) · Leukemia, Myeloid (29) · Bone Marrow Diseases (28) · Leukemia (26) · Disease Attributes (25)
fludarabine (18) · Cyclophosphamide (15) · Whole-Body Irradiation (8) · Melphalan (7) · fludarabine phosphate (7) · Thiotepa (6) · Busulfan (5) · Mesna (5) · Tacrolimus (5) · Antilymphocyte Serum (4) · Cytarabine (4) · Methotrexate (4) · thymoglobulin (4) · Blood Specimen Collection (3) · Filgrastim (3)
Massachusetts General Hospital (11) · Duke University (8) · St. Jude Children's Research Hospital (8) · Dana-Farber Cancer Institute (7) · Assistance Publique - Hôpitaux de Paris (5) · Brigham and Women's Hospital (5) · First Affiliated Hospital of Zhejiang University (4) · M.D. Anderson Cancer Center (4) · Masonic Cancer Center, University of Minnesota (4) · Memorial Sloan Kettering Cancer Center (4) · Nantes University Hospital (4) · Ruijin Hospital (4) · Mount Sinai Hospital, Canada (3) · National Cancer Institute (NCI) (3) · Abramson Cancer Center at Penn Medicine (2)
United States (123) · China (31) · France (19) · Canada (9) · Italy (8) · Germany (7) · Israel (4) · Spain (4) · United Kingdom (4) · Egypt (3) · Switzerland (3) · Turkey (Türkiye) (3) · Australia (2) · Czechia (2) · Denmark (2)
Yi Luo, M.D. (4) · Areej El-Jawahri, MD (3) · Hermioni Amonoo, MD, MPP, MPH (3) · Anthony Sung, MD (2) · Chenyu Lin, MD (2) · Dolores Grosso, DNP, CRNP (2) · Fang Liu, MD, PhD (2) · Hongyu Zhang, MD, PhD (2) · Joanne Kurtzberg, MD (2) · Ken Takeshita, MD (2) · Neal Flomenberg, MD (2) · Patrick C Johnson, MD (2) · Swati Naik, MBBS (2) · Adam Binder, MD (1) · Adam Lamble, MD (1)
PMID 22009536, PMID 25419693, PMID 25742699, PMID 26822328, PMID 29269796, PMID 31704264, PMID 32519455, PMID 33022376, PMID 33579774, PMID 34649555, PMID 34670600, PMID 35017254, PMID 35397575, PMID 35436209, PMID 35667558, PMID 36027848, PMID 36028757, PMID 36106394, PMID 36163030, PMID 36452492, PMID 37328178, PMID 37442349, PMID 37467030, PMID 37655932, PMID 37925363, PMID 38473278, PMID 38485149, PMID 38597262, PMID 38752789, PMID 38781564, PMID 38833312, PMID 38906793, PMID 39080734, PMID 39293082, PMID 39606939, PMID 39706761, PMID 39828642, PMID 39886490, PMID 39954038, PMID 40056908, PMID 40101246, PMID 40204300, PMID 40534493, PMID 41225624, PMID 41269781, PMID 41721625, PMID 42159161, PMID 42454903, PMID 42495646
2025 (2), P30CA012197 (2), 2019 (1), 2023 (1), K08CA251654 (1), K08CA279500 (1), K08CA283026 (1), K08HL143189 (1), K12CA167540 (1), P30CA008748 (1), R01CA223963 (1), R01CA292116 (1), R03CA270671 (1), R21AG041489 (1), R21CA267275 (1)